LeConte Wealth Management LLC Makes New $467,000 Investment in Johnson & Johnson $JNJ

Key Points

• LeConte Wealth Management LLC has made a new investment in Johnson & Johnson by acquiring 2,818 shares worth approximately $467,000 during the first quarter.
• The company reported a quarterly earnings per share (EPS) of $2.77, exceeding analysts' expectation of $2.68, with revenue of $23.74 billion reflecting a 5.8% increase year-over-year.
• Johnson & Johnson has announced a quarterly dividend of $1.30 per share, which will be paid on September 9th, representing an annualized dividend yield of 2.9%.

LeConte Wealth Management LLC acquired a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,818 shares of the company's stock, valued at approximately $467,000.

Several other institutional investors have also recently bought and sold shares of the business. Elios Financial Group Inc. increased its holdings in Johnson & Johnson by 1.5% during the first quarter. Elios Financial Group Inc. now owns 4,496 shares of the company's stock worth $746,000 after buying an additional 66 shares during the last quarter. Atlantic Family Wealth LLC increased its holdings in Johnson & Johnson by 4.4% during the first quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company's stock worth $266,000 after buying an additional 67 shares during the last quarter. MBA Advisors LLC increased its holdings in Johnson & Johnson by 1.2% during the first quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock worth $921,000 after buying an additional 68 shares during the last quarter. Sovereign Financial Group Inc. increased its holdings in Johnson & Johnson by 1.8% during the first quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock worth $651,000 after buying an additional 69 shares during the last quarter. Finally, Nabity Jensen Investment Management Inc increased its holdings in Johnson & Johnson by 1.5% during the first quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company's stock worth $767,000 after buying an additional 69 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. UBS Group raised their price objective on shares of Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a report on Thursday, July 17th. Guggenheim restated a "neutral" rating and set a $167.00 price objective (up previously from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Bank of America increased their target price on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research report on Thursday, July 17th. Morgan Stanley increased their target price on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Finally, Barclays increased their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Nine analysts have rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson presently has an average rating of "Moderate Buy" and an average target price of $174.50.

Johnson & Johnson Price Performance

Shares of JNJ stock traded down $0.38 during trading hours on Monday, reaching $176.26. The stock had a trading volume of 9,283,816 shares, compared to its average volume of 8,411,460. The stock's fifty day simple moving average is $161.70 and its 200 day simple moving average is $158.60. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $177.57. The firm has a market capitalization of $424.49 billion, a PE ratio of 18.85, a PEG ratio of 2.25 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same period last year, the business earned $2.82 earnings per share. Johnson & Johnson's revenue was up 5.8% compared to the same quarter last year. On average, equities research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 3.0%. Johnson & Johnson's payout ratio is presently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.